iNova Pharmaceuticals announces the launch of iPitch 2020
Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.
iPitch is a collaborative crowdsourcing program that allows product and packaging developers, innovators, licensors and certified manufacturers to connect with iNova and share their great ideas for healthcare products that have the potential for commercialisation.
It provides a wonderful opportunity for anyone with new and different ideas or next-generation solutions that may not have the resources or expertise to bring their innovations to market, or just looking for a commercialisation partner.
According to iNova Executive Director and Head of Innovation, Filomena Maiese, “We know there’s consumer health product innovations out there that haven’t yet been commercialised. We want to partner with them.”
iPitch specifically looks for effective, evidence-based products with innovative and new formats and formulations. After creating a lot of buzz last year, and by leveraging the power of global connectivity, the 2019 iPitch received hundreds of different and diverse product and formulation ideas from around the world. iNova is currently preparing to launch two of these products into the marketplace, which otherwise would not have had a chance to make it to consumers.
Entries for iPitch can be made according to criteria set out by iNova within a range of set ‘challenges’. This year, iNova has created and carefully selected a diverse set of challenges across which submissions can be made. This provides more opportunity for innovators to submit entries and captures ideas across a wide range of consumer healthcare needs. The challenges cover products from pregnancy supplements to packaging to face masks to cough, cold and flu formulations.
iNova is excited about building a number of new mutually beneficial business partnerships through iPitch. According to Chief Executive Officer, Dan Spira, “iNova has a strong track record of acquiring, building and launching trusted consumer healthcare brands, which makes us a great partner of choice for product owners and licensors globally”.
iNova has a diverse range of market-leading products. They have a trusted reputation among consumers and healthcare professionals and are recognised as an innovative partner of choice in the healthcare industry. With a multi-national business platform, it offers access to well-established operating platforms and broad distribution networks across Asia, Africa and ANZ.
iPitch will be open for applications for 12 weeks, ending 21 August 2020.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.